文献速递肝病

纤维化与炎症参与肝硬化心肌病发病机制

Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-11

一项前瞻性研究纳入52例肝硬化患者和14名健康对照,采用对比增强MRI定量心肌和肝脏细胞外容积(ECV),并检测胶原转化和炎症生物标志物。结果显示患者心肌和肝脏ECV均升高,且心肌ECV与肝脏ECV及胶原形成和炎症标志物相关。结论认为结构心肌改变似乎与肝纤维化密切相关,炎症和纤维化在肝硬化心肌病结构异常发展中可能起作用。

要点

  • 肝硬化患者心肌ECV(31.2±5.5%)和肝脏ECV(44.1±9.6%)均高于健康对照。
  • 心肌ECV与肝脏ECV强相关(r=0.48),并与胶原形成和炎症标志物相关。
  • 肝ECV由胶原形成标志物预测,心肌ECV由胶原形成和炎症标志物预测。

核心结论

  • 结构心肌改变似乎与肝硬化患者的肝纤维化密切相关;与胶原形成和炎症标志物的强关联为炎症和纤维化在结构性心脏异常(可能进展为肝硬化心肌病)中的作用提供了新见解。

研究设计与样本

  • 前瞻性研究,纳入52例肝硬化患者和14名健康对照;所有患者接受对比增强MRI及T1成像定量心肌和肝脏ECV,并检测胶原转化和炎症生物标志物。

主要发现

  • 心肌ECV在患者为31.2±5.5%,健康对照为27.4±2.9%(P=0.037);肝脏ECV在患者为44.1±9.6%,健康对照为33.7±6.7%(P<0.001)。
  • 心肌ECV与肝脏ECV强相关(r=0.48,P=0.001),并与胶原形成和炎症生物标志物相关(P<0.005)。
  • 肝脏ECV与胶原形成和炎症生物标志物相关(P<0.003)。
  • 多变量分析中,肝脏ECV由胶原形成标志物(PRO-C3和PRO-C6)预测,心肌ECV由胶原形成标志物(PRO-C6)和炎症标志物(IL-6和sMR)预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibrogenesis and inflammation contribute to the progression of cirrhosis. However, it is unknown if these processes also contribute to the development of cirrhotic cardiomyopathy (CCM). Novel magnetic resonance imaging with quantification of the extracellular volume (ECV) provides an estimate of the fibrotic remodelling in the liver and heart. AIM: To investigate the relationship between liver and cardiac ECV in cirrhosis and their association with collagen turnover and inflammation. METHODS: A prospective study of 52 patients with cirrhosis and 14 healthy controls. All patients underwent contrast-enhanced MRI with T1-mapping and quantification of myocardial and liver ECV, biochemical assessments of collagen turnover (PRO-C3, PRO-C5, PRO-C6, collagen type IV degradation fragment, collagen type V degradation fragment, LG1M) and inflammation (TNFα, IL-1β, IL-6, IL-8, IL-18, SDF1α, sCD163, sMR, soluble macrophage mannose receptor). RESULTS: Myocardial and liver ECV were increased in patients compared with healthy controls (myocardial ECV 31.2 ± 5.5% vs 27.4 ± 2.9%, P = 0.037; liver ECV 44.1 ± 9.6% vs 33.7 ± 6.7%, P < 0.001). Myocardial ECV correlated strongly with liver ECV (r = 0.48, P = 0.001) and biomarkers of collagen formation and inflammation (P < 0.005). Similarly, liver ECV correlated with biomarkers of collagen formation and inflammation (P < 0.003). In a multivariate analysis, liver ECV was predicted by biomarkers of collagen formation (PRO-C3 and PRO-C6), whereas myocardial ECV was predicted by biomarkers of collagen formation (PRO-C6) and inflammation (IL-6 and sMR). CONCLUSION: Structural myocardial changes seem closely related to liver fibrosis in patients with cirrhosis. The strong associations with biomarkers of collagen formation and inflammation provide new insight into the role of inflammation and fibrogenesis in the development of structural cardiac abnormalities, potentially leading to CCM.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wiese S, Voiosu A, Hove JD, et al. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther. 2020. PMID: 32524673. doi:10.1111/apt.15812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。